ASH 2023 | Epcoritamab + R-Mini-CHOP in previously untreated DLBCL: insights from EPCORE NHL-2
R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) is the standard of care for patients with previously untreated diffuse large B-cell lymphoma (DLBCL). However, full-dose treatment is not feasible in elderly or frail patients or patients with comorbidities. Joshua Brody, MD, Tisch Cancer Institute Mount Sinai, New York, NY, presents the initial data from arm 8 of the EPCORE NHL-2 trial (NCT04663347), showing a high complete metabolic response (CMR) rate and overall response rate (ORR) in full-dose-ineligible patients treated with subcutaneous (SC) epcoritamab in combination with low-dose R-CHOP treatment (R-Mini-CHOP). This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Research Funding: SeaGen, Merck, BMS, Pharmacyclics, ADC Therapeutics, Epizyme, Genentech, Inc., Kite
Consultancy: SeaGen, Merck, BMS, Pharmacyclics, ADC Therapeutics, Epizyme, Genentech, Inc., Kite
